Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction

The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI). Glycoprotein IIb/IIIa inhibitors enhance thrombolysis. The role of combination therapy in clinical practice remains to be established. Patients (n =...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2003-04, Vol.41 (8), p.1251-1260
Main Authors: Giugliano, Robert P., Roe, Matthew T., Woodlief, Lynn H., Harrington, Robert A., Hannan, Karen L., Califf, Robert M., Gibson, C.Michael, Zeymer, Uwe, Van de Werf, Frans, Baran, Kenneth W., Hobbach, Hans-Peter, Greenberg, Sally, Miller, Joanne, Kitt, Michael M., Strony, John, McCabe, Carolyn H., Braunwald, Eugene
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI). Glycoprotein IIb/IIIa inhibitors enhance thrombolysis. The role of combination therapy in clinical practice remains to be established. Patients (n = 438) with STEMI
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(03)00123-2